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were the main significant determinants of non-adherence. Country differences explained 11% of the variance in non-adherence.
Conclusions:
Amongst the variables measured, patients' adherence to antihypertensive medicines is influenced primarily by their self-efficacy, illness beliefs and perceived barriers. These should be targets for interventions for improving adherence, as should an appreciation of differences among the countries in which they are being delivered.
INTRODUCTION [First-level Header]
Adherence to antihypertensive treatments is sub-optimal (1), even among patients participating in clinical studies, whose median persistence with medicines is only about one year (2) . Patients who are poorly adherent (proportion of days covered ≤40%) (3) experience significantly increased risk of acute cardiovascular events, compared to those who adhere adequately (≥80%), and incur greater health care costs (4) . The World Health Organisation (5) has called for further research to gain a better understanding of the determinants of non-adherence to antihypertensive medicines, and to identify common risk factors for non-adherence across different countries, in order to inform strategies for improving patient adherence.
Known determinants of non-adherence to antihypertensive treatments may broadly be categorised to factors related to the patient (6) (7) (8) (9) and their familial and cultural context (10) , condition (11) , treatment (8, 11) , socioeconomics, and health professional / health care system (5, 12) . Components of sociocognitive and self-regulatory theory including attitude (13) , perceived behavioural control (13) (14) , low self-efficacy (13, (15) (16) , lack of perceived treatment benefits (11) , perceived barriers (7) (8) , illness perceptions (6, 10) , beliefs about medicines (6, 11, (17) (18) and lack of social support (10, (19) (20) are significantly associated with non-adherence. Studies based on consumer demand theory support the negative impact of the costs of medicines on adherence (21) , but there is a lack of empirical evidence on alternative behavioural economic theories such as time preference. We are unaware of any study in which a range of these factors has been tested simultaneously to assess their combined contribution to non-adherence across several countries.
The aim of this study, therefore, was to identify determinants of patient non-adherence to antihypertensive medicines, drawing from psychosocial and economic models of behaviour, from a cross-sectional survey across a number of European countries with contrasting cultures, health care systems and patient characteristics.
METHODS [First-level Header]
The research used an online, convenience cross-sectional sample of adults with hypertension recruited from 11 European countries. We tested the contribution of multiple, theory-driven determinants for association with antihypertensive treatment nonadherence, and reported our findings according to the STROBE (STrengthening the Reporting of OBservational studies in Epidemiology) statement on cross-sectional studies (22) .
Procedure
[Second-level Header]
Following receipt of ethical approval from all relevant committees we invited ambulatory, adult patients with hypertension to participate in an online questionnaire.
Patients self-selected into this study in response to advertisements placed in community pharmacies (Austria, Belgium, England, France, Germany, Greece, Netherlands, Portugal, Poland, Wales) or hypertension clinics (Hungary). Additional strategies were necessary to increase recruitment in some countries. These included recruiting patients via general practice surgeries (Poland, Hungary), placing advertisements in the press (England, Wales), and using online patient support groups (Poland). No incentive was offered for patients to participate. The survey was administered anonymously through SurveyMonkey ® , with one entry allowed per Internet Protocol address to reduce the chance of multiple responses. Patient information sheets, consent forms and eligibility checks, were provided online.
Inclusion criteria [Second-level Header]
We included patients who consented, and who self-reported as being: aged ≥18 years, diagnosed by a doctor as having hypertension that lasted at least 3 months, currently prescribed antihypertensive medicine(s), and personally responsible for administering their medicines.
Exclusion criteria [Second-level Header]
Respondents who self-reported as being diagnosed with a "psychiatric condition" or those living in a nursing home (or similar facility) were excluded.
Potential determinants [Second-level Header]
Potential determinants of non-adherence were identified from published literature reviews (23) (24) . The questionnaire was developed from validated instruments, where available, and covered: participant demographics, use of medicines, self-rated health (25) , and a battery of scales derived from economic (21) and sociocognitive (23) (24) theories.
Affordability and cost-related behaviours were assessed by a dichotomous question asking whether respondents had to think about the money available to spend when obtaining their medicines and six related items, each measured on a 5-point Likert scale (26) . Components of the European Social Survey (27) assessed household income:
participants reported their main source of income, their total annual income (in bands), whether they were coping with their present income and the ease or difficulty in borrowing money when in need. We assessed participants' time preference for near, versus distant enjoyment of health benefits (28) . The internationally standardised EUROPEP measure (29) assessed participants' evaluations of the health care they receive.
Validated, self-report tools were used to assess personal and socio-cognitive determinants of non-adherence. Dispositional optimism was measured using the Life Orientation Test (LOT-R) on 5-point Likert scales (30) . Illness representations were measured using the Brief Illness Perception Questionnaire (B-IPQ) (31) that assessed personal beliefs about illness consequence, timeline, personal control, treatment control, illness identity, concern about illness, illness coherence and emotional representations (the causal subscale was removed due to translation issues The primary outcome measure was self-reported non-adherence, based on the 4-item Morisky Medication Adherence Scale (37) . This classified patients as being non-adherent according to a single 'yes' response to any of the four questions that made specific reference to "high blood pressure medicine". This validated scale is the most frequently used questionnaire measuring adherence to medication (38) . An exploratory analysis was also conducted of those categorised as intentionally non-adherent based on 'yes' responses to two specific Morisky items which identify non-adherence as a result of feeling better/worse. A secondary outcome measure of adherence was provided by the Medication Adherence Rating Scale (MARS) (39) , which consisted of 5 items rated on a Likert scale with a low score (on a range of 5 -25) indicating lower levels of adherence.
Our choice of outcome measures was informed by the theoretical and empirical literature on medication adherence spanning the behavioural and medical sciences from which the study questions emerged. These two conceptually different measures provided dichotomous data on non-adherence and continuous data on adherence to patients' antihypertensive medications.
The final survey had a total of 135 items.
Translation [Second-level Header]
Measures that were not validated and available in the required language were translated into the appropriate languages using accredited translators who were native speakers of the target languages and fluent in English. Translations were checked for compatibility with the original version in a process of back translation, performed by persons who were native English speakers and fluent in each target language, to ensure that none of the original meaning was lost. For each language, a third individual acted as a reviewer and highlighted any discrepancies between the forward and back translations which were resolved by discussion with the translators. All translations were coordinated by one project partner to ensure consistency. Piloting in each country enabled identification of any semantic inconsistencies.
Sample size [Second-level Header]
Based on an expectation of 30% non-adherence (6) and a one-sided, 5% level of significance, 323 completed Morisky scores were required per country for within-country analyses.
Data analysis [Second-level Header]
Responses to the survey were coded in SPSS version 19 (IBM Corporation) and analysed in Stata version 10 (StataCorp LP). We assumed missing data to be missing at random and imputed using multiple imputations by chained equations (MICE) (40) , to create 25 data sets for each country. For a single incomplete variable, multiple imputation constructs a model relating the incomplete variable to variables in the prediction model, and draws from the posterior predictive distribution of the missing data, conditional on the observed data. Using MICE, imputed values were initialised by drawing at random from observed values. Imputation of missing data was performed on variables ordered by level of 'missingness', using observed and current imputed values of all predictors. To ensure stability, this imputation step was cycled 10 times for each of the 25 imputed data sets (41) . Analyses were performed on each set and imputation-specific coefficients were pooled according to Rubin's rules (42) . Imputed data were used for all analyses with the exception of demographic variables where data from complete cases were used.
In the primary analysis, we calculated the percentage of patients classed as non-adherent according to Morisky score in each country. Potential associations with non-adherence were initially tested univariately using χ 2 and independent samples t-tests (associations with medicines use were adjusted for age), followed by a logistic regression with nonadherence as the dependent variable. We applied a bivariate method of selecting explanatory variables, whereby only variables found to be significant (p<0.05) in the univariate analysis were entered into the regression model based on a theoretical order (43) (44) , from determinants classified as demographic and medicines use characteristics (distal) to attitudes and behaviours (proximal). Assumptions regarding multicollinearity, singularity, normality, linearity, and homoscedasticity were tested and met. Country comparison analysis was conducted using χ 2 tests. We adopted a similar approach for the secondary outcome of MARS adherence, but with a one-way ANOVA to test differences among countries.
In order to account for variance both within-country and between-country, as a secondary analysis, 2-level multilevel regression models with respondents nested within country were specified for both Morisky (logit model) total and intentional non-adherence, and MARS adherence (linear regression model). Multilevel models with random intercepts and fixed effects were specified, initially with all variables common to all countries. Noncontributory variables were subsequently removed iteratively, determined by highest pvalue using backwards elimination (based on p>0.05). We calculated the variance partition coefficient (45) , to determine the attribution of country to the observed variance in non-adherence.
A complete case analysis of Morisky total non-adherence was performed to assess the sensitivity of our main findings to assumptions relating to missing data. In a post hoc analysis, we assessed the impact of excluding Hungary from the analysis, given that Hungary alone recruited patients from hypertension clinics.
RESULTS [First-level Header]
Participants: A total of 2630 adults from 11 countries completed the questionnaire. Target recruitment was achieved in 5 countries (Austria, England, Hungary, Poland and Wales).
Study set-up and initiation was delayed in Belgium, Germany, Greece and The Netherlands leading to non-target recruitment. The analysis therefore includes these 9 countries which each recruited over 100 participants (n=2595). There was an inadequate level of available research support in France and Portugal that resulted in low response (n=11, n=33 respectively) and these were excluded from the analysis. Included participants' characteristics are presented in Table 1 . The overall level of missing data by country ranged from 5% to 26%, with lowest rates seen on demographic and clinical questions (0-8%), MARS (<2%), medicine necessity and concerns (14%) and selfefficacy (14%) and highest rates seen on the income questions (22%), time preference (22%) and BRIGHT barriers (23%) ( Fig. 1 ).
There were significant differences between country samples on all demographic and clinical characteristics assessed. Self-rated health was more often rated as poor or fair in Poland (48.6%) and Hungary (47.6%) than in Belgium (16.1%), England (19.5%) and
Wales (19.8%). Fewer respondents from Hungary, Greece and Poland had received higher education than in other countries. Respondents from Greece tended to be older and more predominantly female, and together with Hungary and Austria, had the greatest number of co-morbidities and were more likely to be taking medicines more frequently than 3 times per day.
Insert Table 1 and Figure 1 Prevalence of non-adherence [Second-level Header]
Based on Morisky scores, non-adherence was least prevalent in the Netherlands, and most prevalent in Hungary ( Table 2 ). Intentional non-adherence was highest in Greece.
Polish respondents had significantly lower levels of adherence, as measured by MARS, than respondents from other countries.
Insert Table 2 Associations with Morisky non-adherence and MARS adherence [Second-level Header]
Among demographic factors, only age showed associations across several countries with younger age associated with Morisky non-adherence in Austria, Belgium, Netherlands and Wales (Table 3) , and older age associated with MARS adherence in the Netherlands (Table 4 ). Unemployment was associated with non-adherence in England and Hungary only. None of the medicines-related factors showed associations with non-adherence in more than one country. The perceived ease or difficulty in borrowing money was associated with non-adherence in England and Germany and having available strategies to cope with the costs of medicines were significantly associated with MARS-rated adherence in Belgium, England, Greece and Hungary.
No significant associations were evident for optimism but in contrast, beliefs about the illness did play a significant role. B-IPQ factors of low perceived illness consequences, low concern about illness, and low beliefs in personal control over illness were significantly associated with non-adherence on the Morisky scale in Austria, Greece
Poland and Wales (Table 3) ; and high belief in treatment control, high illness coherence, high belief in personal control significant in Austria, Greece and Hungary based on MARS assessment of adherence (Table 4 ). Illness identity, perceived illness timeline and emotional representations were not significant, neither were beliefs about medicines, in terms of their necessity or concerns about taking them (BMQ).
The socio-cognitive variables, drawn mainly from the theory of planned behaviour (TPB), did not emerge consistently in the inter-country analysis. Perceived barriers to adherence (whether changes to daily routine makes taking medicines more difficult) were related only to non-adherence in Greece, although a high number of barriers assessed by the BRIGHT (35) (36) were associated with non-adherence in Austria and Poland.
Intention to adhere was associated with adherence in Hungary and Wales. Low selfefficacy, however, emerged significant in relation to non-adherence in all countries except the Netherlands, and high self-efficacy explained adherence in all countries except
Poland. Social support factors emerged significant only in Hungary but in a counterintuitive direction, in relation to low perceived environmental support and greater adherence.
The variables examined in this study explained between 13.4% and 65.2% of the variability in MARS adherence (Table 4 ).
Insert Tables 3 and 4 Multilevel about illness and difficulty in borrowing money as being significantly associated with non-adherence (Table 5 ). Associations were consistent in the model specified with
Morisky intentional non-adherence. Multilevel linear regression found older age, a lower level of education, a greater number of medicines, less frequent dosing, having low perceived barriers, low perceptions of illness consequences, beliefs in treatment control, and high self-efficacy were connected to higher adherence as measured by MARS. Based on the Morisky scale, 11% and 7% of explained variances in total and intentional nonadherence were attributable to differences among countries; and 23% of the variance in adherence based on MARS was attributable to differences among countries.
Sensitivity analysis [Second-level Header]
The analysis of complete cases resulted in less precise estimators, as expected, altering the significance of some variables and hence their inclusion in the final model. Selfefficacy and perceived barriers (BRIGHT), however, remained significant as in the primary analysis.
When Hungary was excluded from the multilevel model (due to the aforementioned difference in recruitment method), we observed a reduction in between-country variance in Morisky non-adherence (from 11% to 4%). Other factors emerged as being significant, including education, number of medical conditions, attitudes and intention to adhere; though self-efficacy and barriers remained significant.
DISCUSSION [First-level Header]
Self-reported non-adherence to antihypertensive medicines is prevalent, even among the sampled population who were in receipt of a current prescription for antihypertensive treatment. Prevalence differs significantly across countries but while a proportion of this variance is explained by country-level effects and demographic characteristics, our principal finding is that potentially modifiable factors of low perceived self-efficacy and, to a lesser extent, low personal control beliefs, and high perceived barriers are consistently associated with non-adherence. Perceived barriers to adherence included forgetfulness or interruption of daily routine, practical difficulties, and feeling overwhelmed by circumstances or complexity of regimen. Our finding of common associations with non-adherence across different countries supports the importance of these factors, particularly given the significant differences that exist in cultural, medical practices and health care systems that contribute to a small proportion of the variance in non-adherence.
Adherence is generally explained by the converse of the above but additionally, costrelated behaviour (i.e. strategies to cope with the cost of prescriptions) and intention also emerged as significant in several countries. The multilevel analysis of all countries show that whilst many factors act in the opposite direction depending on whether we are addressing non-adherence or adherence, some uniquely explain non-adherence e.g. employment status, low normative beliefs, low personal control, low illness concern, and low borrowing potential; and others uniquely explain adherence e.g. lower education, low perceived illness consequences, (both these are counter-intuitive) and beliefs in treatment control. The multilevel analyses also suggest that where possible, a reduction in dose frequency and number of prescribed medicines might achieve improvements in adherence.
The literature on adherence to medicines contains many analyses that have tested the significance of clinical, treatment and demographic characteristics as predictors of nonadherence, assuming that behaviour is a function of these characteristics alone. This approach has significant limitations. Our analysis is rooted in behavioural theories to reflect the notion that individual beliefs and social influences are potentially more relevant determinants of intentional and non-intentional non-adherence (and of adherence) than relatively fixed attributes of the person or their clinical situation.
Previous studies have shown that, based on socio-cognitive and self-regulation theories, personal and perceived control (6, 10, 13, (15) (16) , perceived benefits of treatment (7, 11) and perceived barrierssuch as forgetfulness and experienced or anticipated side effects (7, 8) are significant predictors of non-adherence in patients taking antihypertensive medicines. Associations between higher levels of self-efficacy and adherence in patients with hypertension have been noted previously (13, 46) . 2 : 191.52 df: 8 p = 0.000 Tests cross country difference in self-reported non-adherence χ 2 : 108.87 df: 8 p = 0.000 Tests cross country difference in self-reported intentional nonadherence, as a proportion of all self-reported non-adherence ANOVA F-test: 106.08 -115.49 † (Complete case F: 103.24) p = 0.000 *95% CI of mean based on imputed data †Range of imputation specific statistics 24 20 6, 7, 8, 9, 15, 16, 17, 19, 20, 25 1, 9, 10, 13, 15, 17, 19, 20, 25 9 (6), Perception of income: Coping (7) , Perception of income: Finding it difficult (8) , Affordability problem (9), Cost coping strategies (10), Time preference: long (11), Time preference: short (12) , Prescriber of medicines (13) , Gender of prescriber (14) , Satisfaction with practitioner (15), Satisfaction with practice (16), Optimism (17) , Timeline (18) , Treatment control (19) , Illness coherence (20) , Emotional representations (21) , Necessity of medicines (22) , Concern about medicine (23), Attitude (24) , Intention (25) , Social Support (26) + As χ 2 cannot be pooled, we report the range of imputation specific χ 2 . The degrees of freedom per imputation is given by (number of variables -1). Imputation-specific, pvalues were p < 0.001 in all cases, with the exception of 3 imputations in Belgium (which were p=0.001, 0.001, 0.002). For the logit model σe 2 = π 2 /3 Variance partition coefficient, VPC = σu 2 /( σu 2 + σe 2 )
Full model specification: age, sex, education, marital status, employment, number of medical conditions, number of different medicines, number of tablets, dosing frequency, number of items prescribed, health status, affordability problem, optimism, necessities, concerns about medicine, attitudes, normative beliefs, barrier (theory of planned behaviour), facilitators, intention, self-efficacy, prescriber of medicines, gender of prescriber, satisfaction with practitioner, satisfaction with practice, barriers (averaged as one less collected in Wales), social support, illness consequences, illness timeline, personal control, treatment control, illness symptomaticity, concern about illness, illness coherence, emotional representations, income source, income perception, ease of borrowing, total income. 
